RESUMO
BACKGROUND: Tuberculosis remains a public health threat responsible as recently as 2018 for more than one million deaths. Chemoprophylaxis with isoniazid is one of the strategies implemented to control the disease. Although it is not yet widely prescribed, its utilization raises additional questions in the "test and treat" era of for anti-retroviral therapy. The objective of this study is to review the different randomized controlled trials of antitubercular Isoniazid Preventive Therapy (IPT). We have distinguished (a) "efficacy trials" (ET) comparing IPT to a placebo or the absence of chemoprophylaxis and (b) "IPT regimen trials" (RT) comparing IPT to one or several other regimens. METHODS: Literature search (keywords from published articles found in the Medline and Scopus data bases: "tuberculosis", "prophylaxis", "HIV", "randomized controlled trial") and standardized reading of selected articles reporting results from randomized trials of IPT in HIV-infected people. RESULTS: Eighteen selected trials (11 ET and 7 RT), including 19,725 participants. The regimens studied were 3H, 6H, 9H, 12H, 12H, 36H/2RZ, 3RH, 3RZ, 3RHZ, and 3HP [H: Isoniazid, R: Rifampicin, Z: Pyrazinamide, P: Rifapentine]. LOCATIONS: Ten in Africa, three in Haiti, one in India, one in the USA, one in the Americas and two multi-continental trials. In ET with or without antiretrovirals (ART), IPT significantly reduces the risk of tuberculosis, by 32 to 71%. In ET prior to ART, IPT does not appear to reduce mortality. In ET in patients receiving ART, on the other hand, IPT reduces mortality. As regards RT, there seems to be no reason to prefer other regimens to IPT. Tolerance is good. Importantly, IPT may reduce (rather than worsen) the risk of multidrug-resistant bacilli selection by decreasing the number of TB episodes and, consequently, the number of curative tuberculosis treatments. CONCLUSION: Far from becoming obsolete due to ARV treatment, IPT has remained a timely and relevant intervention.
Assuntos
Infecções por HIV , Tuberculose , Humanos , Isoniazida/uso terapêutico , Antituberculosos/uso terapêutico , Tuberculose/tratamento farmacológico , Tuberculose/epidemiologia , Tuberculose/prevenção & controle , Antirretrovirais/uso terapêutico , Infecções por HIV/tratamento farmacológico , Infecções por HIV/epidemiologia , Infecções por HIV/prevenção & controle , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
Tuberculous meningitis (TBM) is the most severe and disabling form of tuberculosis (TB), with at least 100,000 cases per year and a mortality rate of up to 50% in individuals co-infected with human immunodeficiency virus type 1 (HIV-1). To evaluate the efficacy and safety of an intensified anti-tubercular regimen and an anti-inflammatory treatment, the INTENSE-TBM project includes a phase III randomised clinical trial (TBM-RCT) in four countries in sub-Saharan Africa (SSA). Within this framework, we designed a comprehensive capacity-building work package ensuring all centres had, or would acquire, the ability to conduct the TBM-RCT and developing a network of skilled researchers, clinical centres and microbiology laboratories. Here, we describe these activities, identify strengths/challenges and share tools adaptable to other projects, particularly in low- and lower-middle income countries with heterogeneous settings and during the coronavirus disease 2019 (COVID-19) pandemic. Despite major challenges, TBM-RCT initiation was achieved in all sites, promoting enhanced local healthcare systems and encouraging further clinical research in SSA. In terms of certified trainings, the achievement levels were 95% (124/131) for good clinical practice, 91% (39/43) for good clinical laboratory practice and 91% (48/53) for infection prevention and control. Platform-based research, developed as part of capacity-building activities for specific projects, may be a valuable tool in fighting future infectious diseases and in developing high-level research in Africa.
The INTENSE-TBM project aimed to design a comprehensive work-package on capacity building, ensuring all centres would acquire the ability to conduct a phase III randomised clinical trial on TBM in sub-Saharan Africa, to reduce tuberculous meningitis mortality and morbidity in patients with/without HIV-1 co-infection. Therefore, the INTENSE-TBM project is an example of how an international clinical research consortium can provide opportunities to enhance local capacity building and promote centres without previous experience in clinical research. This article provides practical approaches for implementing effective capacity-building programmes. We highlight how to overcome limitations imposed by the COVID-19 pandemic to successfully complete clinics, laboratory set-ups and personnel training, so as to optimise resources and empower African institutions on a local level. At the same time, our experience shows how capacity-building programmes can deliver long-lasting impact that extends beyond the original aims of the project (e.g. HIV and TB), and support local health systems in fighting other infectious disease (e.g. COVID-19). Research projects in low- and lower-middle income countries with heterogeneous settings could stand to benefit the most.
RESUMO
The nucleotide substitution G1896A on the precore (pc) region has been implicated in virological and serological responses during treatment in hepatitis B virus (HBV)-infected patients. Whether this mutation affects the therapeutic course of HIV-HBV co-infected patients, especially from Western Africa, is unknown. In this prospective cohort study, 86 antiretroviral (ARV)-naïve HIV-HBV co-infected patients from Côte d'Ivoire, initiating ARV-treatment containing lamivudine (n = 53) or tenofovir (n = 33), had available baseline pc sequences. Association of the pcG1896A mutation with time to undetectable HBV-DNA, hepatitis B "e" antigen (HBeAg) seroclearance (in HBeAg-positive patients), and hepatitis B surface antigen (HBsAg) seroclearance was evaluated using Cox proportional hazards regression. At ARV-initiation, median HBV-DNA was 6.04 log10 copies/mL (IQR = 3.70-7.93) with 97.7% harbouring HBV genotype E. Baseline pcG1896A mutation was identified in 51 (59.3%) patients, who were more commonly HBeAg-negative (P < .001) and had basal core promotor A1762T/G1764A mutations (P < .001). Patients were followed for a median 36 months (IQR = 24-36). Cumulative proportion of undetectable HBV-DNA was significantly higher in patients with baseline mutation (pcG1896A = 86.6% vs no pcG1896A = 66.9%, P = .04), but not after adjusting for baseline HBV-DNA levels and anti-HBV agent (P = .2). No difference in cumulative proportion of HBeAg seroclearance was observed between mutation groups (pcG1896A = 57.1% vs no pcG1896A = 54.3%, P = .7). Significantly higher cumulative proportion of HBsAg seroclearance was observed in patients without this mutation (pcG1896A = 0% vs no pcG1896A = 36.9%, P < .001), even after adjusting for baseline HBsAg quantification and anti-HBV agent (P < .001). In conclusion, lacking the pcG1896A mutation before ARV initiation appeared to increase HBsAg seroclearance rates during treatment. The therapeutic implications of this mutation need further exploration in this setting.
Assuntos
Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Antivirais/uso terapêutico , Antígenos de Superfície da Hepatite B/sangue , Antígenos E da Hepatite B/genética , Vírus da Hepatite B/genética , Hepatite B/tratamento farmacológico , Infecções Oportunistas Relacionadas com a AIDS/epidemiologia , Infecções Oportunistas Relacionadas com a AIDS/virologia , Adulto , África Ocidental/epidemiologia , Antirretrovirais/uso terapêutico , DNA Viral/sangue , Feminino , Genótipo , Hepatite B/epidemiologia , Hepatite B/virologia , Antígenos do Núcleo do Vírus da Hepatite B/genética , Antígenos E da Hepatite B/sangue , Vírus da Hepatite B/imunologia , Humanos , Lamivudina/uso terapêutico , Masculino , Mutação , Regiões Promotoras Genéticas , Estudos Prospectivos , Tenofovir/uso terapêuticoRESUMO
OBJECTIVE: Assessing the use of high-dose fluconazol monotherapy (1200mg or 800mg) in the treatment and prognosis of HIV-associated cryptococcal meningitis in Ivory Coast. PATIENTS AND METHODS: A retrospective study carried out from August 2008 to August 2011 based on patients charts suffering from CM in the Abidjan Tropicals and Infectious Disease Unit. Mortality rate and associated factors were analyzed. RESULTS: Forty-six cases of cryptococcal meningitis (2.5% of hospitalizations) were included. The sex-ratio was of 1.2. The median age was 40.5 [35-47] years. The symptomatology was subacute (93.5%). The main clinical symptoms were syndrome of pure meningeal irritation (65%), fever (100%); 35% of patients had encephalomeningits. Twenty-one (45.7%) was ART-naïve patients. Fluconazole 1200mg was prescribed to 29 (63%) patients. Therapeutic lumbar punctures were performed in 42 (91.3) patients. The mortality rate was 50%. Significant predictors of mortality were encephalomeningitis and therapeutic lumbar puncture. CONCLUSION: Cryptococcal meningitis associated mortality remains high despite the use of high-dose fluconazole monotherapy. Therapeutic lumbar punctures help to improving the prognosis.
Assuntos
Antifúngicos/administração & dosagem , Fluconazol/administração & dosagem , Meningite Criptocócica/tratamento farmacológico , Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Infecções Oportunistas Relacionadas com a AIDS/epidemiologia , Adulto , Côte d'Ivoire/epidemiologia , Relação Dose-Resposta a Droga , Feminino , HIV , Infecções por HIV/tratamento farmacológico , Infecções por HIV/epidemiologia , Humanos , Masculino , Meningite Criptocócica/epidemiologia , Pessoa de Meia-Idade , Estudos RetrospectivosRESUMO
SETTING: TEMPRANO was a multicentre, open-label trial in which human immunodeficiency virus (HIV) infected adults with high CD4 counts were randomised into early or deferred antiretroviral therapy (ART) arms with or without 6-month isoniazid preventive therapy (IPT) in a setting where the World Health Organization (WHO) recommends IPT in HIV-infected patients. Despite the WHO recommendation, IPT coverage remains low due to fear of the presence of undiagnosed active TB before prescribing IPT, and the related risk of drug resistance. OBJECTIVE: To report the frequency of undiagnosed TB in patients enrolled for IPT and describe the results of a 1-month buffer period to avoid prescribing IPT for active TB cases. DESIGN: Patients were screened using a clinical algorithm and chest X-ray at Day 0 and started on isoniazid at Month 1 if no sign/symptom suggestive of TB appeared between Day 0 and Month 1. RESULTS: Of 1030 patients randomised into IPT arms. 10% never started IPT at Month 1. Of these, 23 had active TB, including 16 with prevalent TB. Among the 927 patients who started IPT, 6 had active TB, including 1 with prevalent TB. Only 1 patient with active TB received IPT due to the 1-month buffer period between Day 0 and IPT initiation. CONCLUSION: In this study, 1.6% of adults considered free of active TB based on clinical screening at pre-inclusion actually had active TB.
Assuntos
Antituberculosos/administração & dosagem , Isoniazida/administração & dosagem , Programas de Rastreamento/métodos , Tuberculose/diagnóstico , Infecções Oportunistas Relacionadas com a AIDS/diagnóstico , Infecções Oportunistas Relacionadas com a AIDS/prevenção & controle , Adulto , Fármacos Anti-HIV/administração & dosagem , Contagem de Linfócito CD4 , Farmacorresistência Viral , Feminino , Seguimentos , Infecções por HIV/tratamento farmacológico , Infecções por HIV/virologia , Humanos , Masculino , Fatores de Tempo , Tuberculose/prevenção & controleRESUMO
Le dépistage systématique du cancer du col de l'utérus chez les femmes infectées par le Vih est recommandé par l'oMS et effectif en Côte d'ivoire depuis 2009. l'objectif était de partager l'expérience de cette pratique en routine chez les femmes infectées par le Vih suivies dans un service d'infectiologie à abidjan. il s'est agit d'une étude rétrospective des dossiers de patientes âgées de 25 à 65 ans, infectées par le Vih, suivies au SMiT entre 2010 et 2014. la technique d'inspection visuelle à l'acide acétique (iVa) a été utilisée pour le dépistage. les données socio-démographiques, cliniques et thérapeutiques recueillies ont été analysées à l'aide des logiciels excel 2007 et STaTa version 13.0. le test statistique utilisé pour comparer les pourcentages était le khi deux ou le test exact de Fischer. les différences observées ont été considérées comme significatives en dessous de 5 %. la variable d'intérêt était la réalisation d'au moins un test iVa en routine. Selon le résultat du test iVa, le profil clinique et immunovirologique des patientes a été analysé en précisant la conduite à tenir selon l'indication. enfin la poursuite du dépistage a été notifiée dans le temps spécifiquement chez les femmes négatives au test initial. entre 2010 et 2014, 4 368 femmes infectées par le Vih étaient éligibles au dépistage du cancer du col. Parmi elles, 301 femmes (6,9 %) en ont bénéficié. l'âge médian était de 38 ans [25 - 58 ans]. la médiane des Cd4 au bilan de suivi lors du test iVa était de 291 cellules/mm3 [2 1 876 cellules/mm3]. le dépistage était positif pour 24 femmes (8 %) et selon les indications, 6 femmes étaient éligibles à la cryothérapie (26 %), 6 à la résection à l'anse diathermique (26 %) et 10 à la réalisation d'un frottis cervico-vaginal, pour une suspicion de cancer invasif (44 %). les patientes positives au test iVa étaient relativement plus jeune (35 vs 38 ans ; p = 0,03). aucun contrôle ultérieur n'a été effectué chez 90 % (n = 249) de celles qui ont eu un test iVa négatif au premier dépistage. le dépistage systématique est peu réalisé en routine au cours du suivi des femmes Vih. les défis opérationnels doivent être relevés pour une optimisation des soins en afrique
RESUMO
With the introduction of more efficient treatments for hepatitis C virus (HCV), improved epidemiological information is required at the country level to allow evidence-based policymaking for elaboration of national strategies and HCV resources planning. We present a systematic review with meta-analysis of HCV seroprevalence data in adults in African countries. We conducted a systematic review of all HCV seroprevalence estimates reported in African countries from 2000 to 2014 in MEDLINE, AJOL and grey literature. We assessed studies performed in the general population and among blood donors, pregnant women and HIV-positive patients. A meta-regression analysis was used to provide adjusted estimates of HCV seroprevalence in the general adult population in each country, accounting for the heterogeneity in sample age structure and population types in the included studies. We identified 775 national-level estimations, among which 184 were included. Estimates of HCV seroprevalence were produced for 38 countries, in addition to the results from nationwide representative surveys available in Egypt and Libya. Next to Egypt, which clearly stands out, the highest levels of seroprevalence were found in Middle Africa (e.g. Cameroon, Gabon and Angola) and some West African countries (e.g. Burkina Faso, Benin), and the largest absolute numbers of infected adults were found in Nigeria, Ethiopia and Democratic Republic of Congo. This study exposes the diversity of HCV epidemiology among African countries. Egypt and several countries of West and Middle Africa present a HCV burden that will require strong governmental commitment to promote efficient preventive and curative interventions.
Assuntos
Hepacivirus/imunologia , Hepatite C/epidemiologia , Adulto , África/epidemiologia , Humanos , Estudos SoroepidemiológicosRESUMO
OBJECTIVE: We described the use of antiretroviral drugs to prevent HIV transmission among children and adolescents victims of rape in Abidjan (Ivory Coast). MATERIALS AND METHOD: We conducted a retrospective and descriptive study on children (0-9 years) and adolescents (10-19 years) victims of rape between 2000 and 2013. We analyzed the patients' socio-demographic characteristics and the modality of the chemoprophylaxis. RESULTS: We included 10 children and 89 adolescents in the study. The median age was 16 years old (3-19 years). The median time to consultation was 23.5 hours (5-152 hours). The antiretroviral chemoprophylaxis was administered to 92 patients (93%). No HIV and HBV seroconversion was observed after a 3-month follow-up. CONCLUSION: A better management of rape victims is required in Abidjan.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/prevenção & controle , Estupro , Adolescente , Fármacos Anti-HIV/administração & dosagem , Criança , Pré-Escolar , Côte d'Ivoire , Feminino , Seguimentos , Anticorpos Anti-HIV/sangue , Infecções por HIV/transmissão , Soropositividade para HIV , Necessidades e Demandas de Serviços de Saúde , Hepatite B/transmissão , Anticorpos Anti-Hepatite B/sangue , Humanos , Masculino , Estudos Retrospectivos , Soroconversão , Fatores Socioeconômicos , Adulto JovemRESUMO
OBJECTIVE: We had for aim to describe the epidemiological, clinical, biological, and outcome features of dengue fever in Abidjan, in 2010. PATIENTS AND METHODS: We retrospectively studied the files of patients hospitalized for dengue fever in 2010, in Abidjan. The diagnosis was made on clinical symptoms and positive dengue PCR and/or IgM. RESULTS: Seven patients were included (5 men, 2 women, median age of 51years [31-65years]). They presented with a febrile pain syndrome (n=7), jaundice (n=3), rash (n=2), and hematemesis complicated by thrombocytopenia (n=6) and leukopenia (n=5). Three patients had a positive IgM serology and 4 had a positive dengue PCR for DENV-3. The outcome was favorable for 6 patients, and 1 patient died of severe hemorrhage. CONCLUSION: The authors advocate the implementation of epidemiological surveillance of dengue and vector control in the Ivory Coast.
Assuntos
Dengue/diagnóstico , Dengue/epidemiologia , Adulto , Aedes/virologia , Idoso , Animais , Anticorpos Antivirais/sangue , Côte d'Ivoire/epidemiologia , Vírus da Dengue/imunologia , Vírus da Dengue/isolamento & purificação , Monitoramento Epidemiológico , Feminino , Humanos , Imunoglobulina M/sangue , Insetos Vetores/virologia , Masculino , Pessoa de Meia-Idade , Estudos RetrospectivosRESUMO
BACKGROUND: Buruli Ulcer (BU)-HIV co-infection is an important emerging management challenge for BU disease. Limited by paucity of scientific studies, guidance for management of this co-infection has been lacking. METHODS: Initiated by WHO, a panel of experts in BU and HIV management developed guidance principles for the management of BU-HIV co-infection based on review of available scientific evidence, current treatment experience, and global recommendations established for management of HIV infection and tuberculosis. RESULTS: The expert panel agreed that all BU patients should be offered quality provider-initiated HIV testing and counselling. In areas with high prevalence of malaria and/or bacterial infections, all patients with HIV co-infection should be started on cotrimoxazole preventative therapy. Combination antibiotic treatment for BU should be commenced before starting antiretroviral therapy (ART) and provided for 8 weeks duration. The suggested combination is rifampicin (10 mg/kg daily up to a maximum of 600 mg/day) plus streptomycin (15 mg/kg daily). An alternative regimen is rifampicin plus clarithromycin (7.5 mg/kg twice daily up to a maximum of 1000 mg daily) although due to drug interactions with antiretroviral drugs this regimen should be used with caution. ART should be initiated in all BU-HIV co-infected patients with symptomatic HIV disease (WHO clinical stage 3 or 4) regardless of CD4 cell count and in asymptomatic individuals with CD4 count ≤500 cells/mm(3) . If CD4 count is not available, BU-HIV co-infected individuals with category 2 or 3 BU disease should be offered ART. For eligible individuals, ART should be commenced as soon as possible within 8 weeks after commencing BU treatment, and as a priority in those with advanced HIV disease (CD4 ≤ 350 cells/mm(3) or WHO stage 3 or 4 disease). All co-infected patients should be actively screened for tuberculosis before commencing BU treatment and before starting ART. Programmes should implement a monitoring and reporting system to document the outcomes of BU-HIV interventions. CONCLUSIONS: Knowledge of the clinical and epidemiological interactions between BU and HIV disease is limited. While awaiting more urgently needed evidence, current management practice of both diseases has been useful to build simple 'common sense' preliminary guidance on how to manage BU-HIV co-infection.
Assuntos
Antibacterianos/uso terapêutico , Fármacos Anti-HIV/uso terapêutico , Úlcera de Buruli/tratamento farmacológico , Coinfecção/tratamento farmacológico , Guias como Assunto , Infecções por HIV/tratamento farmacológico , África , Úlcera de Buruli/complicações , Úlcera de Buruli/epidemiologia , Contagem de Linfócito CD4 , Coinfecção/epidemiologia , Doenças Endêmicas , Infecções por HIV/complicações , Infecções por HIV/epidemiologia , Humanos , Combinação Trimetoprima e Sulfametoxazol/uso terapêuticoRESUMO
The objective of this study is to describe the clinical, biological, therapeutic and evolving current profile of hospitalized patients with HIV infection in the cohort of the Infectious and Tropical Diseases Unit (ITDU) in the aim to improve their care management. This is a retrospective study, conducted on medical data of hospitalized cases of patients with HIV infection in the ITDU at the teaching hospital of Treichville (Abidjan) from 2006 to 2007. During the two years, 447 patients were included in the study. Their average age was 39 years [18 years-86 years] and sex ratio was 0.69. Of the 447 patients, 35% were unemployed and 67% were new patients who had never undergone antiretroviral therapy (ART). The duration of drug exposure was less than 6 months in 59% of treated patients. The average time to initiate ART was seven weeks. Among naive patients 41.9% were lost to follow up, 35.9% were waiting for treatment and 22.1% waiting for baseline biological test to initiate ART. At the initiation of ART, 79.6% of patients had a CD4 count less than 200/mm(3). The reasons of hospitalization defining AIDS were dominated by tuberculosis (34.2%), cerebral toxoplasmosis (17.9%) and neuromeningeal cryptococcosis (8%). The main reasons of hospitalization in classifying non-AIDS were pyelonephritis (6.5%), bacterial pneumonia (5.4%) and undetermined infectious encephalitis (4.9%). Hospital mortality was 24.4%. The leading causes of death were tuberculosis (22.9%), cerebral toxoplasmosis (20.2%), undetermined infectious encephalitis (18.3%) and cryptococcal meningitis (13.7%). The profile of PLHIV in hospital is characterized by profound immunosuppression due to late diagnosis and high mortality associated with severe opportunistic infections and late initiation of ART.
Assuntos
Infecções por HIV/epidemiologia , Infecções por HIV/terapia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Côte d'Ivoire/epidemiologia , Progressão da Doença , Feminino , Infecções por HIV/complicações , Infecções por HIV/diagnóstico , Unidades Hospitalares/estatística & dados numéricos , Hospitalização/estatística & dados numéricos , Humanos , Masculino , Pessoa de Meia-Idade , Fatores Socioeconômicos , Adulto JovemRESUMO
Introduction : L'efficacite des traitements antiretroviraux (ARV) peut entrainer des phenomenes inflammatoires de restauration immune (IRIS) ou auto-immuns paradoxaux sous forme de pathologies infectieuses telles que la tuberculose ou la cryptococcose. Observation: Nous rapportons un cas inhabituel de syndrome inflammatoire de restauration immune sous la forme d'une cryptococcose disseminee avec des atteintes meningees et cerebrales chez un patient de 56 ans infecte par le VIH-1 qui a consulte pour un trouble de la vigilance; des crises convulsives et une hemiparesie droite. Le patient avait repondu favorablement a un traitement antifongique par fluconazole institue pour une meningite a cryptocoque un mois avant son admission. Un traitement ARV avait ete initie une dizaine de jours apres le traitement anticryptococcique. Apres deux semaines effective de traitement ARV; le tableau clinique etait marque par la reapparition des symptomes neuro-meninges et leur aggravation. L'examen a l'encre de chine du liquide cephalorachidien (LCR) mettait en evidence des spores de Cryptococcus neoformans. La recherche de l'antigene cryptococcique etait positive et la culture sur milieu de Sabouraud montrait des colonies de Cryptococcus Neoformans. L'IRM cerebrale notait de multiples lesions d'abces. L'evolution a ete fatale apres 11 jours de traitement. Conclusion : Le cryptococcome associe a l'IRIS est peu decrit en Afrique. La generalisation actuelle des ARV sur ce continent pourrait entrainer une recrudescence de cette manifestation
Assuntos
Síndrome Inflamatória da Reconstituição Imune , Meningite CriptocócicaRESUMO
OBJECTIVE: To describe the epidemiological and clinical features and the outcome of tetanus with a surgical wound (open fracture, burn, incision, curettage, etc) as the portal of entry. METHODS: Cross-sectional analysis of records of patients hospitalized in the department of infectious and tropical diseases in Abidjan for surgical tetanus from 2003 to 2008. RESULTS: During the 6-year study period, 29 cases were identified. They accounted for 11% of all tetanus cases admitted to the hospital: 8% from 2003 through 2006 and 14% in 2007 and 2008. The patients' average age was 36 years (range: 11-72). Most cases (86%) involved recent surgery, in both public (51%) and private (49%) health facilities. All patients had generalized tetanus at admission, and 24 (86%) paroxysms. Moderate forms predominated (69%). The lethality of tetanus in these surgical wound cases was 45%. The characteristics statistically associated with death were: age >44 years, time of hospitalization >4 days, the presence of paroxysms, and a Dakar prognosis score ≥4. CONCLUSION: The severity of surgical tetanus remains a concern for practitioners. Its high prevalence in recent years demonstrates the need to increase surgeons' awareness of tetanus prevention.
Assuntos
Infecção da Ferida Cirúrgica , Tétano , Adolescente , Adulto , Idoso , Criança , Côte d'Ivoire , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Infecção da Ferida Cirúrgica/diagnóstico , Infecção da Ferida Cirúrgica/epidemiologia , Tétano/diagnóstico , Tétano/epidemiologia , Adulto JovemRESUMO
OBJECTIVE: To present epidemiological and clinical aspects of human rabies in a hospital center. METHOD: We analyzed medical records of cases of rabies in humans treated at the infectious disease department of the Treichville University Hospital Center from January 2005 through December 2009. RESULTS: Seven cases of human rabies were reported during those five years, four in teenagers and three in adults. Five of the cases involved bites by stray dogs whose vaccine status was unknown. No patient had had a pre-exposure prophylactic vaccination, and only four post-exposure prophylaxis, all incomplete. All of the patients developed furious rabies and fever 21 to 96 days (mean: 47.7) after the dog bite, when the wounds had healed and scars formed. Death occurred 4 to 10 days after the onset of symptoms (mean: 4.7). Relatives refused autopsies in all cases. CONCLUSION: It is indispensable to increase population awareness of prevention by vaccination against human rabies, reduce the population of stray dogs, and promote mass vaccination of dogs in the Ivory Coast.
Assuntos
Raiva/epidemiologia , Adolescente , Adulto , Criança , Côte d'Ivoire/epidemiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos RetrospectivosRESUMO
OBJECTIVE: The authors had for aim to describe the management of cryptococcal meningitis in HIV infected adults, in Ivory Coast. PATIENTS AND METHODS: A retrospective study was made from January 1, 2005 to December 31, 2008 on the files of consecutive hospitalized patients presenting with cryptococcal meningitis, at the Treichville University Hospital, Infectious and tropical diseases department (Abidjan). The socio-demographic, clinical, and biological aspects as well as the outcome were analyzed. RESULTS: Eighty patients presenting with cryptococcal meningitis, (2.6% of hospitalized patients) were included: 41 men (51.25%) and 39 women (48.75%); mean age: 40 years (range 26 to 58 years). The delay before consultation was 5.4 days, range 2-12 days). The mains symptoms were headache (83.7%), fever (63.7%), and consciousness disorders (60%). Meningo-encephalitis accounted for 75% of the clinical presentations; 54 patients (67.5%) were naive of antiretroviral treatment (mean CD4: 45/mm(3) (range 5-103/mm(3)), while 26 (32.5%) had received antiretrovirals before presenting with cryptococcal meningitis (Nadir CD4=81/mm(3)). Amphotericin B relayed by fluconazole was prescribed to 86.2% of the patients, associated with a therapeutic lumbar puncture for 30 patients. The death rate was 41.2%. CONCLUSION: In spite of antiretroviral treatment availability in Ivory Coast, cryptococcal meningitis remains frequent with a high death rate. This study stresses the importance of early management to improve the prognosis.
Assuntos
Terapia Antirretroviral de Alta Atividade , Infecções por HIV/complicações , Infecções por HIV/tratamento farmacológico , Meningite Criptocócica/complicações , Adulto , Côte d'Ivoire , Feminino , Humanos , Masculino , Meningite Criptocócica/epidemiologia , Pessoa de Meia-Idade , Estudos RetrospectivosAssuntos
Adenina/análogos & derivados , Fármacos Anti-HIV/efeitos adversos , Síndrome de Fanconi/induzido quimicamente , Organofosfonatos/efeitos adversos , Adenina/efeitos adversos , Idoso , Alcinos , Fármacos Anti-HIV/administração & dosagem , Fármacos Anti-HIV/uso terapêutico , Terapia Antirretroviral de Alta Atividade , Benzoxazinas/administração & dosagem , Benzoxazinas/uso terapêutico , Côte d'Ivoire , Ciclopropanos , Quimioterapia Combinada , Enterobacter aerogenes/isolamento & purificação , Infecções por Enterobacteriaceae/complicações , Síndrome de Fanconi/complicações , Feminino , Infecções por HIV/complicações , Infecções por HIV/tratamento farmacológico , HIV-1 , Humanos , Lamivudina/administração & dosagem , Lamivudina/uso terapêutico , Lopinavir , Malária/complicações , Masculino , Pessoa de Meia-Idade , Pielonefrite/complicações , Pielonefrite/microbiologia , Pirimidinonas/administração & dosagem , Pirimidinonas/uso terapêutico , Ritonavir/administração & dosagem , Ritonavir/uso terapêutico , TenofovirRESUMO
OBJECTIVE: The aim of this study was to assess the tolerability and adherence to all non-occupational post-exposure prophylaxis (PEP) for cases of HIV exposure in Abidjan. METHOD: We retrospectively studied all post-exposure prophylaxis for non-occupational exposures to HIV prescribed from January 1st, 2000 to December 31st, 2007 in the Abidjan infectious diseases department. We analyzed the types of exposure, socio-demographic characteristics of patients, antiretroviral therapy regimens, adherence and tolerability, duration of the treatment, and post-exposure follow-up. RESULTS: Over these eight years, we managed 128 consultations for non-professional exposures to HIV (50 male [39%], 78 female patients [61%]), average age 24.8 years (four-54 years). The most frequent exposures were due to rape (n=74), condom rupture (n=29), and occasional unprotected sex (n=21). The average delay before consultation was 20.8 hours. The antiretroviral chemoprophylaxis included a protease inhibitor in 93% of the cases; 80.5% of patients completed 28 days of chemoprophylaxis, while 8.6% interrupted the treatment, and 10.9% were lost to follow-up. The most frequent adverse effects were gastrointestinal, reported by 79 patients (61.7%). Only 34 patients (26.6%) returned for clinical and biological post-exposure follow-up with HIV control at third month, without documented seroconversion. CONCLUSION: Cases of sexual exposure to HIV are the main indication for post-exposure prophylaxis in Abidjan, except for occupational exposure to blood. However, post-exposure prophylaxis should be available in the units of primary care, such as emergencies departments.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/prevenção & controle , Profilaxia Pós-Exposição , Adolescente , Adulto , Fármacos Anti-HIV/administração & dosagem , Fármacos Anti-HIV/efeitos adversos , Mordeduras Humanas , Criança , Pré-Escolar , Preservativos , Côte d'Ivoire , Falha de Equipamento , Feminino , Gastroenteropatias/induzido quimicamente , Infecções por HIV/transmissão , Inibidores da Protease de HIV/administração & dosagem , Inibidores da Protease de HIV/efeitos adversos , Inibidores da Protease de HIV/uso terapêutico , Soropositividade para HIV , Humanos , Masculino , Pessoa de Meia-Idade , Ferimentos Penetrantes Produzidos por Agulha , Cooperação do Paciente , Profilaxia Pós-Exposição/estatística & dados numéricos , Estupro , Estudos Retrospectivos , Resultado do Tratamento , Sexo sem Proteção , Adulto JovemRESUMO
OBJECTIVE: We studied the evolution of drug combinations used, as well as the clinical and immunological profile of patients at initiation of highly active antiretroviral therapy (HAART) between 1996 and 2006 in West Africa. SETTINGS AND METHOD: IeDEA West Africa is a network of HIV care programs established in 2006. We analyzed data from 12 clinical centers treating adults in five countries: Benin, Cote d'Ivoire, Senegal, Gambia, and Mali. Patients 16 years of age or over were included in the study and the following was documented: sex, date of birth and date of initiation of HAART. RESULTS: We included 14,496 adult patients having started HAART, among these 55 % had started HAART between 2005-2006. The proportion of HIV-infected women increased from 46 % in 1996-2000 to 63 % in 2005-2006. The median age at HAART initiation remained constant: 35 years for women and 40 years for men. The proportion of patients having started HAART with a CD4 count<200 cells/microl was 54 % in 1996-2000, and 64 % in 2005-2006. The most frequently prescribed HAART was: AZT/3TC (or d4T/DDI)/IDV (27 %) in 1996-2000; d4T (or AZT)/3TC/EFV (49 %) in 2003-2004, and d4T/3TC/NVP (49 %) in 2005-2006. CONCLUSION: The first line HAART regimen recommended by WHO was initiated in 83 % of cases in 2005-2006. New approaches to an earlier initiation of ART should be explored to reduce mortality in HIV-infected patients on HAART.
Assuntos
Terapia Antirretroviral de Alta Atividade/tendências , Infecções por HIV/tratamento farmacológico , Adulto , África Ocidental , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de TempoRESUMO
OBJECTIVE: To evaluate the efficacy of antiretroviral treatment in elderly people followed at the Unit for Infectious and Tropical Diseases at the University Hospital in Abidjan. MATERIAL AND METHODS: We performed a retrospective descriptive study of the files of people aged at least 60 years, infected by HIV who were treated and followed-up in the Unit between 1 January 1999 and 31 December 2006. We analysed sociodemographic (age, sex), clinical (weight, Karnofsky scale, CDC, opportunistic infections), biological (HIV, CD4, haemogram, glycaemia, creatininaemia, transaminasaemia) and therapeutic (antiretroviral regimens, evolution, side-effects) parameters. The efficacy of treatment was evaluated as the percentage of patients with < 200 CD4/ml, and its safety was based on deleterious effects. RESULTS: We studied 62 patients (44 men, 18 women), of whom 13 had been treated (21%), 46 had not been treated (74.2%) and 48 (77.4%) were undergoing chemoprophy-laxis with cotrimoxazole. Most were infected with HIV1 (93.6%), 3.2% with HIV2 and 3.2% with both HIV1 and HIV2. The majority (93.3%) was symptomatic, and 67.8% had AIDS. During 34 months of follow-up, 48 patients (77.4%) received first-line treatment, 13 (21%) received second-line and only one patient (1.6%) had third-line treatment. The percentage of patients with more than 200 CD4/ml increased from 20% at baseline to 36% at 6 months and 39% at 12 months. The main clinical side-effect was peripheral neuropathy (30.5%), and the main biological effect was hypertransaminasaemia > 2N (32.3%). The median rate of loss to follow-up was 17.7%, and two patients (3.2%) died. CONCLUSION: Antiretroviral treatment is effective in the elderly, with few biological disorders. A prospective study of a larger sample would elucidate the differences from younger people in the efficacy of such treatment.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/tratamento farmacológico , HIV-1 , HIV-2 , Infecções Oportunistas Relacionadas com a AIDS/epidemiologia , Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Síndrome da Imunodeficiência Adquirida/epidemiologia , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Fármacos Anti-HIV/efeitos adversos , Contagem de Linfócito CD4 , Doença Hepática Induzida por Substâncias e Drogas/epidemiologia , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Côte d'Ivoire/epidemiologia , Bases de Dados Factuais , Quimioterapia Combinada , Feminino , Seguimentos , Gastroenteropatias/induzido quimicamente , Gastroenteropatias/epidemiologia , Infecções por HIV/epidemiologia , Hospitais Universitários/estatística & dados numéricos , Humanos , Masculino , Pessoa de Meia-Idade , Doenças do Sistema Nervoso Periférico/induzido quimicamente , Doenças do Sistema Nervoso Periférico/epidemiologia , Estudos RetrospectivosRESUMO
Objectif : Evaluer l'efficacite du traitement antiretroviral chez les sujets ages suivis dans le service des Maladies Infectieuses et Tropicales a Abidjan. Materiel et Methodes : Il s'agit d'une etude retrospective; descriptive et portant sur l'analyse des dossiers de sujets ages d'au moins 60 ans; infectes par le VIH; traites et suivis dans le service des Maladies Infectieuses et Tropicales entre le 1er janvier 1999 et le 31 decembre 2006. L'analyse a porte sur les parametres sociodemographiques (age; sexe); cliniques ARV; (poids; score Karnofsky; stade CDC; affections opportunistes); biologiques (type de VIH; CD4; hemogramme; glycemie; creatininemie; transaminasemie) et therapeutiques (regimesA RV; evolution; effets secondaires). L'efficacite du traitement etait basee sur le pourcentage de patients ayant un taux de CD4 200 / ml et la tolerance basee sur les effets deleteres. Resultats : L'etude a concerne 62 sujets ages (44 hommes / 18 femmes); dont 13 pretraites (21); 46 naifs (74;20) et 48 (77;42) sous chimioprophylaxie au cotrimoxazole. La majorite de l'effectif etait infectee par le VIH1 (93;60) contre 3;20pour le VIH2 et 3;20pour le VIH 1+2. Ils etaient symptomatiques a 93;3avec 67;8au stade SIDA. En trente quatre mois de suivi; 48 patients ont recu un regime de premiere ligne (77;4) ; 13 de deuxieme ligne (20;96) et un seul patient avait un regime de troisieme ligne (1;6). L'analyse des resultats a montre que le pourcentage des patients ayant un taux des CD4 200 etait croissant; passant de 20a M0 a 36a M6 puis 39a M12. Quant aux effets secondaires; ils etaient cliniquement domines par les neuropathies peripheriques (30;5) et biologiquement par l'hypertransaminasemie 2N (32;3). Le taux median de perdus de vue etait de 17;7; et 2 patients (3;22) sont decedes. Conclusion : Le traitement ARV est efficace chez les personnes agees avec peu d'anomalies biologiques; aussi; une etude prospective sur un plus grand echantillonnage permettrait-elle de mieux percevoir les differences avec le sujet jeune